Your browser is no longer supported. Please, upgrade your browser.
Settings
BBIO BridgeBio Pharma, Inc. daily Stock Chart
BBIO [NASD]
BridgeBio Pharma, Inc.
Index- P/E- EPS (ttm)-2.55 Insider Own7.60% Shs Outstand117.80M Perf Week6.12%
Market Cap3.91B Forward P/E- EPS next Y-2.74 Insider Trans-25.70% Shs Float69.05M Perf Month8.19%
Income-291.30M PEG- EPS next Q-0.77 Inst Own97.30% Short Float16.35% Perf Quarter11.28%
Sales40.60M P/S96.35 EPS this Y-118.10% Inst Trans-1.87% Short Ratio15.37 Perf Half Y-5.90%
Book/sh3.23 P/B9.78 EPS next Y9.60% ROA- Target Price44.40 Perf Year6.08%
Cash/sh7.31 P/C4.32 EPS next 5Y- ROE- 52W Range14.23 - 48.36 Perf YTD-9.90%
Dividend- P/FCF- EPS past 5Y- ROI-53.30% 52W High-34.70% Beta-
Dividend %- Quick Ratio14.20 Sales past 5Y- Gross Margin93.80% 52W Low121.93% ATR1.79
Employees296 Current Ratio14.20 Sales Q/Q- Oper. Margin- RSI (14)50.33 Volatility5.29% 6.20%
OptionableYes Debt/Eq1.21 EPS Q/Q-46.50% Profit Margin- Rel Volume0.56 Prev Close32.23
ShortableYes LT Debt/Eq1.21 Earnings- Payout- Avg Volume734.57K Price31.58
Recom1.80 SMA200.20% SMA50-0.26% SMA2006.85% Volume412,398 Change-2.02%
Jun-25-20Initiated BofA/Merrill Neutral $38
May-19-20Initiated BTIG Research Buy $49
Apr-13-20Initiated H.C. Wainwright Buy $50
Feb-19-20Initiated Mizuho Buy $51
Jul-26-19Initiated Raymond James Outperform $36
Jul-22-19Initiated SVB Leerink Outperform $34
Jul-22-19Initiated Piper Jaffray Overweight $50
Jul-22-19Initiated JP Morgan Overweight $38
Jul-22-19Initiated Jefferies Buy $38
Jul-22-19Initiated Goldman Buy $42
Jul-22-19Initiated BMO Capital Markets Outperform $49
Jul-10-20 07:30AM  
Jul-06-20 04:30PM  
Jul-05-20 03:43PM  
Jun-25-20 10:10AM  
Jun-24-20 07:30AM  
Jun-18-20 07:35AM  
07:30AM  
Jun-11-20 07:00AM  
Jun-05-20 04:30PM  
02:43PM  
May-29-20 07:30AM  
May-19-20 09:37AM  
May-13-20 04:10PM  
04:01PM  
May-11-20 07:30AM  
May-06-20 04:30PM  
May-05-20 04:30PM  
Apr-08-20 08:56AM  
Apr-06-20 09:53PM  
Apr-03-20 04:30PM  
Mar-12-20 07:30AM  
Mar-04-20 11:32PM  
07:00AM  
Mar-03-20 04:30PM  
Mar-02-20 08:29AM  
Feb-24-20 07:30AM  
Feb-21-20 07:25PM  
Feb-05-20 06:31PM  
Jan-13-20 07:30AM  
Jan-10-20 07:30AM  
Jan-08-20 08:00AM  
Jan-06-20 07:30AM  
Dec-19-19 04:30PM  
Dec-18-19 07:30AM  
Dec-17-19 01:52PM  
Dec-16-19 07:30AM  
Dec-13-19 12:37PM  
Dec-10-19 07:56AM  
Dec-09-19 07:30AM  
Dec-05-19 07:35PM  
Dec-03-19 07:30AM  
Dec-02-19 08:00AM  
Nov-27-19 04:30PM  
Nov-16-19 07:28PM  
05:30PM  
Nov-07-19 04:13PM  
Oct-24-19 03:41PM  
Oct-22-19 07:30AM  
Oct-17-19 07:00AM  
Sep-24-19 07:00AM  
Sep-05-19 04:00PM  
Aug-29-19 09:16PM  
Jul-27-19 01:01PM  
Jul-02-19 01:48PM  
Jun-28-19 03:14PM  
Jun-27-19 12:15PM  
11:25AM  
11:12AM  
09:24AM  
Jun-26-19 11:23PM  
06:43AM  
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 20 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, an oral small molecule transthyretin (TTR), which is ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and achondroplasia; BBP-631, a preclinical adeno-associated virus gene transfer product candidate for the treatment of congenital adrenal hyperplasia caused by 21OHD; and BBP-454, a preclinical development program for small molecule inhibitors of KRAS for the treatment of pan-mutant KRAS-driven cancers. The company also engages in developing products for Mendelian, genetic dermatology, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license agreements with the Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc.; and strategic collaboration agreements with Johns Hopkins University and University of Florida. The company was founded in 2015 and is headquartered in Palo Alto, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kumar NeilCEO and PresidentJul 02Sale30.2256,4451,706,0222,165,372Jul 06 07:18 PM
HENDERSON MICHAEL THOMASChief Business OfficerJul 01Option Exercise0.1610,0001,600270,293Jul 06 05:28 PM
STEPHENSON BRIAN CSee RemarksJul 01Sale30.9310,800334,053294,316Jul 06 05:29 PM
HENDERSON MICHAEL THOMASChief Business OfficerJul 01Sale30.9710,000309,701260,293Jul 06 05:28 PM
Kumar NeilCEO and PresidentJul 01Sale31.0987,0252,705,3352,221,817Jul 06 07:18 PM
Turtle CameronSee RemarksJun 30Option Exercise0.2310,0002,32019,823Jul 02 04:28 PM
Turtle CameronSee RemarksJun 30Sale32.6610,000326,6239,823Jul 02 04:28 PM
HENDERSON MICHAEL THOMASChief Business OfficerJun 08Sale30.0160618,185260,293Jun 10 04:12 PM
Kumar NeilCEO and PresidentJun 08Sale30.0110,600318,1252,308,842Jun 10 04:09 PM
STEPHENSON BRIAN CSee RemarksJun 08Sale30.002,00060,002305,116Jun 10 04:06 PM
STEPHENSON BRIAN CSee RemarksJun 03Sale30.041,60048,072307,116Jun 05 07:59 PM
Kumar NeilCEO and PresidentJun 03Sale30.055,930178,1732,319,442Jun 05 07:55 PM
Kumar NeilCEO and PresidentJun 01Sale29.1980,0002,335,3902,325,372Jun 03 04:06 PM
HENDERSON MICHAEL THOMASChief Business OfficerJun 01Sale29.372,58575,912261,683Jun 03 04:05 PM
STEPHENSON BRIAN CSee RemarksJun 01Sale29.367,200211,401308,716Jun 03 04:06 PM
KKR Genetic Disorder L.P.10% OwnerMay 28Sale33.392,389,69079,791,74934,510,971Jun 01 05:15 PM
HENDERSON MICHAEL THOMASChief Business OfficerMay 26Option Exercise1.0518,36519,283264,268May 27 04:57 PM
HENDERSON MICHAEL THOMASSee RemarksMay 05Sale30.471,46044,493162,362May 06 08:28 PM
STEPHENSON BRIAN CSee RemarksMay 05Sale30.495,706173,959315,916May 06 08:26 PM
Kumar NeilCEO and PresidentMay 05Sale31.0279,6002,469,4822,405,372May 06 08:21 PM
STEPHENSON BRIAN CSee RemarksMay 04Sale30.001,49444,827321,622May 05 06:15 AM
Kumar NeilCEO and PresidentMay 04Sale29.6839,6801,177,6852,484,972May 05 04:05 PM
HENDERSON MICHAEL THOMASSee RemarksMay 04Sale30.011,32039,613163,822May 05 06:13 AM
HENDERSON MICHAEL THOMASSee RemarksMay 01Sale29.272,58575,653165,142May 05 06:13 AM
Kumar NeilCEO and PresidentMay 01Sale29.1440,7201,186,4002,524,652May 05 04:05 PM
STEPHENSON BRIAN CSee RemarksMay 01Sale29.237,200210,474323,116May 05 06:15 AM
Turtle CameronSee RemarksApr 27Option Exercise17.002,00034,00011,823Apr 29 04:05 PM
Turtle CameronSee RemarksApr 27Sale32.012,00064,0289,823Apr 29 04:05 PM
Turtle CameronSee RemarksApr 08Option Exercise17.008,000136,00017,823Apr 10 08:22 AM
Turtle CameronSee RemarksApr 08Sale27.048,000216,3589,823Apr 10 08:22 AM
Kumar NeilCEO and PresidentApr 07Sale25.481,80545,9832,565,372Apr 09 04:05 PM
Kumar NeilCEO and PresidentApr 03Sale25.093007,5282,567,177Apr 06 09:17 PM
Kumar NeilCEO and PresidentApr 02Sale25.0415,778395,1032,567,477Apr 03 04:10 PM
HENDERSON MICHAEL THOMASSee RemarksApr 01Sale26.942,58569,629167,727Apr 03 04:13 PM
STEPHENSON BRIAN CSee RemarksApr 01Sale26.617,200191,610330,316Apr 03 04:11 PM
Kumar NeilCEO and PresidentApr 01Sale26.2662,1171,631,3622,583,255Apr 03 04:10 PM
Kumar NeilCEO and PresidentMar 03Sale32.2820,047647,1482,645,372Mar 04 05:55 PM
Kumar NeilCEO and PresidentMar 02Sale32.2899,9533,226,8832,665,419Mar 04 05:55 PM
STEPHENSON BRIAN CSee RemarkMar 02Sale32.2710,800348,541337,516Mar 04 04:11 PM
HENDERSON MICHAEL THOMASSee RemarksMar 02Sale32.443,975128,965170,312Mar 04 04:06 PM
Turtle CameronSee RemarksFeb 11Option Exercise17.002,00034,00011,823Feb 13 08:48 PM
Turtle CameronSee RemarksFeb 11Sale37.282,00074,5649,823Feb 13 08:48 PM
HOMCY CHARLES JChairman of PharmaceuticalsFeb 10Sale36.0020,000720,0001,342,291Feb 12 07:03 PM
Kumar NeilCEO and PresidentFeb 05Sale34.8730,8931,077,3902,765,372Feb 07 05:40 PM
Kumar NeilSee RemarksFeb 04Sale34.5554,9511,898,3872,796,265Feb 05 05:04 PM
STEPHENSON BRIAN CSee RemarksFeb 04Sale34.524,973171,692348,316Feb 05 04:57 PM
STEPHENSON BRIAN CSee RemarksFeb 03Sale34.905,827203,379353,289Feb 05 04:57 PM
Kumar NeilSee RemarksFeb 03Sale34.9334,1561,193,2232,851,216Feb 05 05:04 PM
HENDERSON MICHAEL THOMASSee RemarksFeb 03Sale34.903,975138,729174,287Feb 05 05:00 PM
HOMCY CHARLES JChairman of PharmaceuticalsJan 14Option Exercise17.0010,000170,0001,372,291Jan 16 07:17 PM
HOMCY CHARLES JChairman of PharmaceuticalsJan 14Sale35.0010,000350,0001,362,291Jan 16 07:17 PM
Turtle CameronSee RemarksJan 08Option Exercise17.0010,000170,00022,630Jan 10 05:15 PM
Turtle CameronSee RemarksJan 08Sale34.3712,807440,2119,823Jan 10 05:15 PM
Kumar NeilSee RemarksJan 03Sale32.2083,9392,702,9562,885,372Jan 06 09:15 PM
HENDERSON MICHAEL THOMASSee RemarksJan 03Sale32.3335811,575178,262Jan 06 09:30 PM
STEPHENSON BRIAN CSee RemarksJan 03Sale32.303,636117,440359,116Jan 06 08:55 PM
STEPHENSON BRIAN CSee RemarksJan 02Sale33.267,164238,243362,752Jan 06 08:55 PM
HENDERSON MICHAEL THOMASSee RemarksJan 02Sale33.263,617120,286178,620Jan 06 09:30 PM
Kumar NeilSee RemarksJan 02Sale33.2636,0611,199,4612,969,311Jan 06 09:15 PM
MCCORMICK FRANKChairman of OncologyDec 30Sale35.8017,150614,0121,261,526Dec 31 04:05 PM
MCCORMICK FRANKChairman of OncologyDec 27Sale37.9282,8503,141,3681,278,576Dec 31 04:05 PM